Terms: = Leukemia AND SYK, P43405, 6850, ENSG00000165025 AND Clinical Outcome
5 results:
1. Sprouty 2: a novel attenuator of B-cell receptor and MAPK-Erk signaling in CLL.
Shukla A; Rai K; Shukla V; Chaturvedi NK; Bociek RG; Pirruccello SJ; Band H; Lu R; Joshi SS
Blood; 2016 May; 127(19):2310-21. PubMed ID: 26809508
[TBL] [Abstract] [Full Text] [Related]
2. Association between B-cell receptor responsiveness and disease progression in B-cell chronic lymphocytic leukemia: results from single cell network profiling studies.
Cesano A; Perbellini O; Evensen E; Chu CC; Cioffi F; Ptacek J; Damle RN; Chignola R; Cordeiro J; Yan XJ; Hawtin RE; Nichele I; Ware JR; Cavallini C; Lovato O; Zanotti R; Rai KR; Chiorazzi N; Pizzolo G; Scupoli MT
Haematologica; 2013 Apr; 98(4):626-34. PubMed ID: 23144194
[TBL] [Abstract] [Full Text] [Related]
3. The degree of BCR and NFAT activation predicts clinical outcomes in chronic lymphocytic leukemia.
Le Roy C; Deglesne PA; Chevallier N; Beitar T; Eclache V; Quettier M; Boubaya M; Letestu R; Lévy V; Ajchenbaum-Cymbalista F; Varin-Blank N
Blood; 2012 Jul; 120(2):356-65. PubMed ID: 22613791
[TBL] [Abstract] [Full Text] [Related]
4. High TCL1 levels are a marker of B-cell receptor pathway responsiveness and adverse outcome in chronic lymphocytic leukemia.
Herling M; Patel KA; Weit N; Lilienthal N; Hallek M; Keating MJ; Jones D
Blood; 2009 Nov; 114(21):4675-86. PubMed ID: 19770358
[TBL] [Abstract] [Full Text] [Related]
5. Variability in the degree of expression of phosphorylated IkappaBalpha in chronic lymphocytic leukemia cases with nodal involvement.
Rodríguez A; Martínez N; Camacho FI; Ruíz-Ballesteros E; Algara P; García JF; Menárguez J; Alvaro T; Fresno MF; Solano F; Mollejo M; Martin C; Piris MA
Clin Cancer Res; 2004 Oct; 10(20):6796-806. PubMed ID: 15501956
[TBL] [Abstract] [Full Text] [Related]
